Cancer Channel
Topics
Medications
Quicklinks
Related Channels

Pertuzumab Dosage

There is only one standard dosage of pertuzumab for everyone who uses this drug to treat breast cancer. Your healthcare provider will administer the medication through an intravenous infusion once every three weeks. The first dose is usually 840 mg, followed by subsequent doses of 420 mg.

An Introduction to Your Dosage of Pertuzumab

Unlike the vast majority of medications used to treat cancer, there is only one standard dose of pertuzumab (Perjeta™), regardless of your age, weight, or any other factors. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
 

Pertuzumab Dosing Guidelines

The first pertuzumab dosage is 840 mg (two vials) given intravenously (by IV) over 60 minutes. After that first dose, the standard dosing regimen is 420 mg of pertuzumab (one vial) given over 30 to 60 minutes by IV, every three weeks.
 
Pertuzumab is meant to be used along with docetaxel (Taxotere®) and trastuzumab (Herceptin®), two other breast cancer medications. If, for whatever reason, you must stop taking trastuzumab, it is recommended that you also stop using pertuzumab; pertuzumab is more effective when used in combination with trastuzumab. However, if you must stop taking docetaxel, you may continue to take trastuzumab and pertuzumab.
 
Pertuzumab sometimes affects the heart and, in severe cases, can cause heart failure. Your heart will be monitored closely. If you develop heart problems, your infusion may need to be delayed or you may need to stop using the drug altogether.
 
If you miss or delay a dose of pertuzumab, you can continue with the 420-mg dosage as long as it has been six weeks or less since the last dosage. If it has been longer than six weeks, you should restart with the higher (840 mg) one-time dosage.
 
4 Relationship Skills for People With ADHD

Pertuzumab Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.